VectorBuilder, a global leader in gene delivery technologies and CDMO solutions, today announced MuteFree™ AAV, a ...

New expedited service line designed for biotechs with timeline constraints, launched in response to client demandCan accelerate timeline to GMP ...

Efficient viral vector production is essential for the cost-effective manufacture of cell and gene therapies. Many of the current production workflows are reliant on basal media in batch-mode, which ...

Medera Inc. ("Medera"), a clinical-stage biopharmaceutical company developing next-generation cardiovascular therapeutics, and its clinical development division Sardocor, today announced that the U.S.

The global gene therapy market size is projected to expand significantly, with an estimated value of USD 19.3 billion by 2034 ...

Improving the therapeutic quality and consistency of cell and gene therapies requires the adoption of enhanced Critical Quality Attributes (CQAs) throughout the development and manufacturing processes ...

With this information in hand, researchers who, for instance, are developing a gene therapy to treat a muscle condition, could use the atlas to identify AAV vectors that preferentially target the ...

For the millions of people living with genetic diseases like muscular dystrophy and inherited liver disorders, one of the ...